Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02569, known as long intergenic non-protein coding RNA 2569, is a nuclear long non-coding RNA transcribed from an enhancer region on chromosome 6. It has been found highly expressed in degenerated nucleus pulposus tissues of the intervertebral disc, and mechanistic studies implicate its role in promoting degeneration and cellular senescence via activation of the NF-κB signaling pathway. Silencing LINC02569 results in reduced inflammation and ECM degradation markers, highlighting its potential as a therapeutic target for intervertebral disc degeneration and related degenerative conditions. Limited disease association outside of IDD has been noted (e.g., glioma susceptibility). No drugs currently modulate this target directly, but siRNA-mediated knockdown demonstrates proof-of-concept therapeutic activity.
Knockdown (using siRNA) of LINC02569 has been shown to attenuate degeneration and senescence in nucleus pulposus cells by blocking NF-κB pathway activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2569 (LINC02569).